Humanigen’s Lenzilumab Selected for COVID-19 Trial

Humanigen’s monoclonal antibody lenzilumab was selected by the NIH’s National Institutes of Allergy and Infectious Diseases for an upcoming clinical trial of potential COVID-19 therapeutics.

The study will evaluate lenzilumab with remdesivir for treatment of hospitalized COVID-19 patients compared to a placebo and remdesivir. Each arm of the trial will enroll 100 patients.

Lenzilumab is currently in phase 3 testing for preventing and treating cytokine storm leading to acute respiratory distress syndrome.